Thyroid Carcinoma Case Study: Lulu
After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.
5 Ways FidoCure Can Expand Your Veterinary Practice
Canine cancer is a heartbreaking diagnosis that affects millions of beloved pets worldwide. In fact, it’s one of the biggest unmet needs in veterinary medicine. As advancements in our field continue to evolve, FidoCure emerges as a groundbreaking solution, offering a revolutionary approach to treating canine cancer. By harnessing the power of genomic testing, FidoCure […]
TCC Case Study: Sir Oliver
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver’s latest CT scan showed a 38% reduction in his bladder tumor.
Mammary Carcinoma Case Study: Missy
After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
Squamous Cell Carcinoma Case Study: Duchess
It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.
Lung Carcinoma Case Study: Adley Hurwitz
After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.
Jejunal Adenocarcinoma Case Study: Callie
With surgery and FidoCure® therapy, Callie is alive and well almost 20 months after her initial diagnosis of jejunal adenocarcinoma.
Osteosarcoma Case Study: Jade
With a combination approach that included FidoCure® therapy, Jade is alive and well 2 years after her initial diagnosis of osteosarcoma.
Insulinoma Case Study: Winston
With a combination approach that included FidoCure®, Winston survived two years following his initial diagnosis of metastatic insulinoma.
FidoCure® Precision Medicine Data Showcased at the American Association of Cancer Research (AACR)
At the AACR 2023 annual meeting, Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials. The first study, titled “High frequency of TP53 mutations in canine skin […]